Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : STEAMROLLER'S DAYTRADES -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (1383)	11/6/1998 12:26:00 PM
From: Laura E.	Respond to of 1561

Bought a few shares of CEXP

To: Henry Niman who wrote (1383)	11/7/1998 9:18:00 AM
From: Ron	Respond to of 1561

GERN in Investors Business Daily today: investors.com key info: Geron has paid for the research using the $14.9 million it netted from its initial public offering in '96. It has also secured more than $44 million in research funding from drug makers Pharmacia & Upjohn Inc., Roche Holdings AG and Japan's Kyowa Hakko. Like most research-stage companies, Geron is bleeding red ink. It lost $9.6 million, or 93 cents a share, in '97. In the first six months of '98, it lost 39 cents. But thanks to its latest discovery, the company is now in a position to partner with large drug makers and genomics outfits to gain new revenue streams. CEO Ron Eastman hopes to secure more partnerships, which he says could soon turn the company profitable.